Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients—a genome-wide association study adjusting for smoking habits

Clozapine (CLZ) is the superior antipsychotic drug for treatment of schizophrenia, but exhibits an extensive interpatient pharmacokinetic variability. Here, we conducted a genome-wide association study (GWAS) of CLZ serum concentration adjusting for known smoking habits, which is a major nongenetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Robert Løvsletten, O’Connell, Kevin, Athanasiu, Lavinia, Djurovic, Srdjan, Kringen, Marianne Kristiansen, Andreassen, Ole A., Molden, Espen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303159/
https://www.ncbi.nlm.nih.gov/pubmed/32555152
http://dx.doi.org/10.1038/s41398-020-00888-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303159/
https://www.ncbi.nlm.nih.gov/pubmed/32555152
http://dx.doi.org/10.1038/s41398-020-00888-1

Ejemplares similares